drugset / Trial / NCT03120494
Evaluating the Feasibility and Acceptability of Implementing a PrEP Program in PR-CoNCRA (San Juan, Puerto Rico)- Part B
Phase 4
Unknown
75 enrolled
Puerto Rico Community Network for Clinical Research on AIDS
Gilead Sciences · collab
NaSingle-groupOpen-labelPrevention
Summary
75 subjects at risk for HIV infection (25 high risk MSM and 50 sero-discordant couples) will be recruited. All subjects will receive Truvada for pre-exposure prophylaxis or PrEP, as well as routine medical evaluations during one year. Subjects will be managed according to CDC's guidelines on the management of PrEP as a tool for HIV prevention.
Timeline
- Start
- 2016-11
- Primary completion
- 2019-06
- Completion
- 2019-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Background | Tenofovir | Small molecule | — | — |
| Background | emtricitabine | Other / unclassified | — | — |